Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Cinclus Pharma Holding AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	48.42	4.58	5.96	10.57	-	-
Revenue Growth (YoY)	-	-23.14%	-43.63%	-	-	-
Gross Profit	48.42	4.58	5.96	10.57	-	-
Selling, General & Admin	49.55	36.85	39.56	64.12	14.45	2.61
Research & Development	191.18	136.66	166.68	157.18	69.82	36.69
Operating Expenses	242.15	173.51	206.24	221.3	84.27	39.29
Operating Income	-193.73	-168.93	-200.28	-210.73	-84.27	-39.29
Interest Expense	-8.29	-8.73	-7.45	-0.08	-0.01	-
Interest & Investment Income	26.19	11.21	3.03	1.18	-	-
Currency Exchange Gain (Loss)	-2.08	-2.08	-10.49	-21.39	8.01	-3.65
Other Non Operating Income (Expenses)	1.24	1.24	0.58	0	0	0
Pretax Income	-176.67	-167.28	-214.61	-231.01	-76.27	-42.94
Income Tax Expense	0.38	0.75	0.51	18.06	-	-
Net Income	-177.05	-168.03	-215.12	-249.07	-76.27	-42.94
Net Income to Common	-177.05	-168.03	-215.12	-249.07	-76.27	-42.94
Shares Outstanding (Basic)	47	37	26	23	21	0
Shares Outstanding (Diluted)	47	37	26	23	21	0
Shares Change (YoY)	45.70%	41.26%	13.81%	9.26%	8415.70%	-
EPS (Basic)	-3.80	-4.54	-8.20	-10.81	-3.62	-173.37
EPS (Diluted)	-3.81	-4.54	-8.20	-10.81	-3.62	-173.37
Free Cash Flow	-103.58	-178.37	-209.19	-192.08	-75.48	-39.47
Free Cash Flow Per Share	-2.23	-4.81	-7.98	-8.34	-3.58	-159.37
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-400.11%	-3688.45%	-3360.98%	-1993.45%	-	-
Profit Margin	-365.66%	-3668.80%	-3609.97%	-2356.20%	-	-
Free Cash Flow Margin	-213.93%	-3894.48%	-3510.42%	-1817.01%	-	-
EBITDA	-193.19	-168.9	-200.25	-210.69	-84.26	-39.28
D&A For EBITDA	0.54	0.03	0.03	0.04	0.01	0.01
EBIT	-193.73	-168.93	-200.28	-210.73	-84.27	-39.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.